Calliditas Therapeutics AB (publ) Stock Forecast, Price & News

-0.31 (-1.14 %)
(As of 04/16/2021 12:00 AM ET)
Today's Range
Now: $26.88
50-Day Range
MA: $28.38
52-Week Range
Now: $26.88
Volume14,993 shs
Average Volume32,682 shs
Market Capitalization$671.22 million
P/E RatioN/A
Dividend YieldN/A
Calliditas Therapeutics AB (publ) operates as a biopharmaceutical company in Stockholm, Sweden. It focuses on identifying, developing, and commercializing pharmaceutical products for patients with unmet medical needs. The company's lead product candidate is Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) also intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.
Calliditas Therapeutics AB (publ) logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CALT
Year FoundedN/A



Sales & Book Value

Annual Sales$19.56 million


Net Income$-3,450,000.00


Market Cap$671.22 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.39 out of 5 stars

Medical Sector

681st out of 2,025 stocks

Pharmaceutical Preparations Industry

327th out of 772 stocks

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
-0.31 (-1.14 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CALT News and Ratings via Email

Sign-up to receive the latest news and ratings for CALT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) Frequently Asked Questions

Is Calliditas Therapeutics AB (publ) a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Calliditas Therapeutics AB (publ) in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Calliditas Therapeutics AB (publ) stock.
View analyst ratings for Calliditas Therapeutics AB (publ)
or view top-rated stocks.

What stocks does MarketBeat like better than Calliditas Therapeutics AB (publ)?

Wall Street analysts have given Calliditas Therapeutics AB (publ) a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Calliditas Therapeutics AB (publ) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ) saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 24,000 shares, an increase of 211.7% from the February 28th total of 7,700 shares. Based on an average trading volume of 24,600 shares, the short-interest ratio is currently 1.0 days. Currently, 0.1% of the shares of the company are sold short.
View Calliditas Therapeutics AB (publ)'s Short Interest

When is Calliditas Therapeutics AB (publ)'s next earnings date?

Calliditas Therapeutics AB (publ) is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Calliditas Therapeutics AB (publ)

How were Calliditas Therapeutics AB (publ)'s earnings last quarter?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) announced its quarterly earnings data on Wednesday, February, 17th. The company reported ($0.79) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.34. The company had revenue of $0.05 million for the quarter.
View Calliditas Therapeutics AB (publ)'s earnings history

What price target have analysts set for CALT?

5 brokerages have issued 1 year price objectives for Calliditas Therapeutics AB (publ)'s stock. Their forecasts range from $28.00 to $52.00. On average, they anticipate Calliditas Therapeutics AB (publ)'s share price to reach $40.80 in the next twelve months. This suggests a possible upside of 51.8% from the stock's current price.
View analysts' price targets for Calliditas Therapeutics AB (publ)
or view top-rated stocks among Wall Street analysts.

Who are Calliditas Therapeutics AB (publ)'s key executives?

Calliditas Therapeutics AB (publ)'s management team includes the following people:
  • Ms. Renee Aguiar-Lucander, Chief Exec. Officer (Age 59)
  • Mr. Fredrik Johansson, Chief Financial Officer (Age 44)
  • Dr. Katayoun Welin-Berger Ph.D., VP of Operations (Age 53)
  • Dr. Johan Haggblad, Chief Scientific Officer (Age 63)
  • Mr. Mikael Widell, Head of Communications & IR (Age 63)
  • Mr. Jonathan A. Schur, Group Gen. Counsel
  • Ms. Ann-Kristin Myde, Head of Clinical Devel. & VP of Project Management (Age 66)
  • Mr. Andrew B. Udell B.Sc., M.B.A., Head of North America - Commercial (Age 51)
  • Dr. Krassimir Mitchev, Head of Medical Affairs (Age 62)
  • Dr. Richard S. Philipson M.D., Chief Medical Officer (Age 56)

Who are some of Calliditas Therapeutics AB (publ)'s key competitors?

What other stocks do shareholders of Calliditas Therapeutics AB (publ) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Calliditas Therapeutics AB (publ) investors own include Ampio Pharmaceuticals (AMPE), Trevena (TRVN), Advanced Micro Devices (AMD), ChromaDex (CDXC), Chimerix (CMRX), CorMedix (CRMD), CTI BioPharma (CTIC), DRDGOLD (DRD), (EQX) and Forte Biosciences (FBRX).

When did Calliditas Therapeutics AB (publ) IPO?

(CALT) raised $179 million in an IPO on Friday, June 5th 2020. The company issued 9,200,000 shares at a price of $19.50 per share. Citigroup, Jefferies and Stifel acted as the underwriters for the IPO and Carnegie was co-manager.

What is Calliditas Therapeutics AB (publ)'s stock symbol?

Calliditas Therapeutics AB (publ) trades on the NASDAQ under the ticker symbol "CALT."

How do I buy shares of Calliditas Therapeutics AB (publ)?

Shares of CALT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Calliditas Therapeutics AB (publ)'s stock price today?

One share of CALT stock can currently be purchased for approximately $26.88.

How much money does Calliditas Therapeutics AB (publ) make?

Calliditas Therapeutics AB (publ) has a market capitalization of $671.22 million and generates $19.56 million in revenue each year. The company earns $-3,450,000.00 in net income (profit) each year or ($0.19) on an earnings per share basis.

How many employees does Calliditas Therapeutics AB (publ) have?

Calliditas Therapeutics AB (publ) employs 34 workers across the globe.

What is Calliditas Therapeutics AB (publ)'s official website?

The official website for Calliditas Therapeutics AB (publ) is

Where are Calliditas Therapeutics AB (publ)'s headquarters?

Calliditas Therapeutics AB (publ) is headquartered at KUNGSBRON 1 C8, STOCKHOLM V7, 11122.

How can I contact Calliditas Therapeutics AB (publ)?

Calliditas Therapeutics AB (publ)'s mailing address is KUNGSBRON 1 C8, STOCKHOLM V7, 11122. The company can be reached via phone at 46-8411-3005 or via email at [email protected]

This page was last updated on 4/17/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.